BioSpace News Archive

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that management will discuss full results from the ILLUMINATE-A Phase 3 study of lumasiran in a webcast conference call on Sunday, June 7, 2020 at 8:30 am ET.

The United States Food and Drug Administration has issued an emergency use authorization for Impella RP to include patients suffering from COVID-19 related right heart failure or decompensation, including pulmonary embolism.

LabCorp, a leading global life sciences company that is deeply integrated in guiding patient care, announced that Covance, its drug development business, has created COVID-19 Clinical Trial Connect in the U.S., a site designed to help people access information about how to participate in COVID-19 research.

As part of its broad-ranging response to help protect frontline healthcare professionals during the COVID-19 pandemic, Honda engineers have developed new methods to use manufacturing equipment to produce critically needed face shields and have donated 70,000 face shields to healthcare workers at 305 medical facilities in 45 states to date with plans to donate another 60,000 in the coming days.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, announced its participation in two upcoming investor conferences.

Spero Therapeutics, Inc. announced that on May 29, 2020, the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 29,500 shares of its common stock to four new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan.

Biomerica also announces its first Japanese patent has been granted for its InFoods® IBS Diagnostic Guided Therapy technology

Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the company received an additional USD 0.5 million in a second installment of the upfront payment from the Chinese company Biotheus Inc. A first installment of USD 0.5 million was received in August 2019 in connection with Alligator entering into a licensing agr

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the Company will be presenting at the Jefferies Virtual Healthcare Conference being held June 2-4, 2020

Histogen Inc. (NASDAQ: HSTO), a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the enrollment of the first patient in its Phase 1b/2a clinical trial of HST 001, the Company’s lead therapeutic candidate for the treatment of androgenic alopecia in men. This blinded, randomized, placebo controlled, single site study will enroll 36 subjects with male pattern hair loss u